| Assessment Status | Rapid Review Complete |
| HTA ID | - |
| Drug | Axitinib |
| Brand | Inlyta® |
| Indication | For the treatment of adult patients with advanced renal cell carcinoma (RCC) after failure of prior treatment with sunitinib or a cytokine |
| Assessment Process | |
| Rapid review commissioned | 07/11/2012 |
| Rapid review completed | 19/11/2012 |
| Rapid review outcome | Full Pharmacoeconomic Evaluation Recommended |
The company has not submitted a HTA dossier to the NCPE therefore the cost effectiveness of the technology could not be proven.